Jason Carroll

Tryptamine Therapeutics Ltd (OTC:TYPTF) has announced that its lead asset, TRP-8803, a psilocin-based IV infusion, will progress to Phase 2 clinical trials following a successful Phase 1b study. TRP-8803 demonstrated significant advantages over oral psilocybin, including rapid onset, precise...

Tryp Therapeutics Inc. (OTCQB:TRYPF), a Canadian biotech leader in psychedelics, has officially received approval from Exopharm Limited shareholders for their strategic merger, paving the way for a new entity, Tryptamine Therapeutics Limited. Key Merger Dates And Trading Halt This approval follows...